Skip Navigation LinksBiobank-Data-Reports

California biobank program

​California Biobank Data Reports​

Biobank Data SB-1099 Report fo​r Calendar Year 2025

California's mandatory Newborn Screening Program (NBS) screens nearly all newborns for certain disorders using dried blood spot specimens collected shortly after birth. Residual dried ​​blood spot specimens are retained by the California Biobank Program to support quality assurance, program evaluation, test development, and validation, and approved public ​he​​alth research, consistent with California law.​

California's voluntary Prenatal Screening Program (PNS) collects blood specimens from pregnant individuals to support prenatal risk assessment and related public health screening activities.

Health and Safety Code section 125010, added by Senate Bill 1099 (Chapter 598, Statutes of 2024), requires the California Department of Public Health to publish annual reports, ​​beginning July 1, 2026, for the preceding calendar year, containing the information specified in subdivision (b) of the statute. The data requested is provided in the table below.

2025 Reporting Requirements​​ Total
(a) The total number of any residual screening specimens stored by the California Biobank Program 29,699,487
(b) The number of new residual screening specimens collected during the previous calendar year 589,449
(c) The number of inheritable conditions identified by the original screening tests during the previous calendar year​

6,552 babies id​​entified with an inheritable disorder ​across 94 disorders

(d) The number of projects utilizing specimens from the California Biobank Program

69 active resea​rch studies​

(e) The number of published research studies using biospecimens from the California Biobank, and the potential health benefits from the research. 13 publications in 2025[1]
(f) The number of specimens provided by the California Biobank Program in 2025 for each research project.

Research Project = 981

Research Project = 783

Research Project = 113

Research Project = 1081

(g) The number of screening tests waived for religious purposes during the previous calendar year 4066
(h) The number of residual screening specimens destroyed at the request of a parent or adult during the previous calendar year 788
(i) The number of residual screening samples remaining to be destroyed at the request of a parent or adult during the previous calendar year. 0

Footnotes

  1. ​​​​Research conducted on residual specimens from the California Biobank (Newborn Screening dried blood spots and Prenatal Screening maternal blood samples) identifies ​risk factors for diseases in women and children; supports the development and evaluation of improved screening tests, prevention strategies, and treatments; and provides potential health benefits through earlier disease detection, better prevention, and more​ effective medical care for affected individuals and families.
Page Last Updated :